Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma
ZURICH, July 22, 2026 /PRNewswire/ -- Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront. The transaction provides the company access to non-dilutive funding for the...
ZURICH, July 22, 2026 /PRNewswire/ -- Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront. The transaction provides the company access to non-dilutive funding for the...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.